Skip to main content
MedicHelpLine
Join Free
Verified Professional Network190+ CountriesHIPAA-Aware Platform
Back to Drug Index
General MedicationsINTRAVENOUS, SUBCUTANEOUSStandard

BORTEZOMIB

BORTEZOMIB

Standard Dose
2.5MG/VIAL
Max Dose
Refer to approved labeling
Primary Use
Review priority: STANDARD Marketing status: Prescription
Summary

Approval overview BORTEZOMIB is listed in Drugs@FDA under application 219167 (ANDA).

Review priority: STANDARD Marketing status: Prescription Active ingredient BORTEZOMIB Form and strength POWDER;INTRAVENOUS, SUBCUTANEOUS - 2.5MG/VIAL Sponsor GLAND Submission history Latest submission status date: 2026-01-06 00:00:00.

Structured Monograph

Clinical summary

Approval overview BORTEZOMIB is listed in Drugs@FDA under application 219167 (ANDA). Review priority: STANDARD Marketing status: Prescription Active ingredient BORTEZOMIB Form and strength POWDER;INTRAVENOUS, SUBCUTANEOUS - 2.5MG/VIAL Sponsor GLAND Submission history Latest submission status date: 2026-01-06 00:00:00. Submission type: ORIG.

Monitoring

  • • Marketing status: Prescription
  • • Review priority: STANDARD

Interaction Notes

  • No interaction notes stored yet.